Revenue
$9.48M
Fiscal year ended 2026-07-31Operating income
-$154.94K
Fiscal year ended 2026-07-31Free cash flow
-$421.36K
Fiscal year ended 2026-07-31Pharma-Bio Serv, Inc. (PBSV) reported revenue of $9.48M and net income of $251.52K for the fiscal year ended 2026-07-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Pharma-Bio Serv, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.
Income
| Metric | 2026-07-31 |
|---|---|
| Revenue | $9.48M |
| Cost of revenue | $6.42M |
| Gross profit | $3.07M |
| Operating income | -$154.94K |
| Net income | $251.52K |
| Research & development | Unavailable |
| Weighted-average diluted shares | shares 68.74M |
| Pretax income | $269.00K |
| Income tax expense | $17.47K |
| Diluted EPS | $0.01 |
| Selling, general & administrative | $3.22M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-07-31 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $11.44M |
| Current assets | $11.24M |
| Total liabilities | $994.74K |
| Current liabilities | $994.74K |
| Total equity incl. NCI | $10.44M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | $2.42M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | Unavailable |
Cash flow
| Metric | 2026-07-31 |
|---|---|
| Operating cash flow | -$414.89K |
| Capital expenditures | $6.47K |
| Investing cash flow | -$303.36K |
| Financing cash flow | -$1.73M |
| Net change in cash | -$2.44M |
| Stock-based compensation | $30.26K |
| Common dividends paid | Unavailable |
| Common share repurchases | $11.59K |
| Depreciation & amortization | $57.94K |
Derived
| Metric | 2026-07-31 |
|---|---|
| Free cash flow | -$421.36K |
| Gross margin | 32.3% |
| Operating margin | -1.6% |
| FCF margin | -4.4% |
| SBC / revenue | 0.3% |
| Current ratio | 11.30x |
| Revenue YoY growth | 3.3% |
| Net margin | 2.7% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 0.1% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | 6.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PBSV in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-09-14View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-K · Filed 2026-01-29View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-Q · Filed 2025-06-16View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.